Finance

Lists
FAE:BME
FAES Farma SA
€4.90
+1.45%
(+0.070) 1D
Nov 4, 5:36:00 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for FAE...
Open
€4.84
High
€4.92
Low
€4.84
Mkt. cap
1.55B
Avg. vol.
199.81K
Volume
59.45K
Dividend
2.61%
Quarterly dividend
€0.03
Ex-dividend date
Jul 2, 2026
P/E ratio
19.06
52-wk high
€5.44
52-wk low
€4.32
EPS
€0.26
Shares outstanding
316.22M
No. of employees
3K
Open
€4.84
High
€4.92
Low
€4.84
Mkt. cap
1.55B
Avg. vol.
199.81K
Volume
59.45K
Dividend
2.61%
Quarterly dividend
€0.03
Ex-dividend date
Jul 2, 2026
P/E ratio
19.06
52-wk high
€5.44
52-wk low
€4.32
EPS
€0.26
Shares outstanding
316.22M
No. of employees
3K
News stories
From web sources and news partners
Profile
Faes Farma, originally Fábrica Española de Productos Químicos y Farmacéuticos, is a Spanish pharmaceutical company based in the Lamiaco district of Lejona in Biscay. Founded on 29 July 1933 by the Serra family with an initial capital of two million pesetas, it pioneered the development of various therapeutic compounds and has been listed on the Madrid Stock Exchange since the 1940s. Faes Farma’s headquarters, production facilities, and R&D center are located in Lejona, with additional offices in Madrid and Barcelona. The group also operates subsidiaries in Portugal, Italy, Mexico, Guatemala, Colombia, Chile, Peru, Bolivia, Ecuador and Nigeria, and maintains an animal nutrition and health division under the name FARM Faes. Wikipedia
About FAES Farma SA
CEO-
Employees2.61K
FoundedJul 29, 1933
Headquarters-
SectorPharmaceutical industry
Industry-
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- / -
Revenue / Est. (EUR)
172.08M / 172.00M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
172.99M
200.07M
191.39M
172.08M
Cost of goods sold
73.44M
61.59M
60.25M
61.07M
Cost of revenue
73.44M
61.59M
60.25M
61.07M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
80.84M
45.67M
44.06M
36.61M
Operating expense
98.44M
100.13M
98.54M
87.49M
Total operating expenses
171.88M
161.72M
158.78M
148.56M
Operating income
1.11M
38.35M
32.61M
23.52M
Other non operating income
1.02M
-
-
-
EBT including unusual items
-1.39M
36.36M
30.47M
20.49M
EBT excluding unusual items
-1.65M
36.36M
30.47M
20.49M
Income tax expense
-7.43M
5.49M
4.32M
3.22M
Effective tax rate
534.46%
15.10%
14.19%
15.73%
Other operating expenses
7.21M
44.62M
44.44M
40.87M
Net income
6.07M
30.79M
26.10M
17.25M
Net profit margin
3.51%
15.39%
13.64%
10.02%
Earnings per share
-
-
-
-
Interest and investment income
-
-
1.41M
-
Interest expense
-3.51M
-1.99M
-3.58M
-2.99M
Net interest expenses
-3.51M
-1.99M
-2.18M
-2.99M
Depreciation and amortization charges
10.39M
9.83M
10.04M
10.02M
EBITDA
6.94M
44.19M
40.50M
29.35M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps